Bifunctional fusion between nerve growth factor and a transferrin receptor antibody

Journal of Neuroscience Research

Volumn 47, Issue 2, 1997, Pages 123-133

  McGrath, John P ^a   Cao, Xueying ^a   Schutz, Adam ^a,e   Lynch, Paul ^b   Ebendal, Ted ^c   Coloma, M Josephina ^d   Morrison, Sherie L ^d   Putney, Scott D ^a  

^a ALKERMES INC   (United States)

^b PERKINELMER INC   (United States)

^c UPPSALA UNIVERSITY   (Sweden)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e GENZYME CORPORATION   (United States)

Author keywords

Alzheimer's disease; blood brain barrier; neurodegeneration; neurotrophic factors

Indexed keywords

COMPLEMENTARY DNA; HYBRID PROTEIN; NERVE GROWTH FACTOR; RECEPTOR ANTIBODY; TRANSFERRIN RECEPTOR;

ANIMAL CELL; ARTICLE; CHIMERA; CHO CELL; GENE EXPRESSION; HYBRIDOMA; MOLECULAR CLONING; NERVE FIBER GROWTH; NONHUMAN; PRIORITY JOURNAL; SPINAL GANGLION; SYMPATHETIC GANGLION;

ANIMALS; ANTIBODY SPECIFICITY; CHIMERA; CLONING, MOLECULAR; DNA, COMPLEMENTARY; GENETIC CODE; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOGLOBULIN VARIABLE REGION; MICE; MOLECULAR SEQUENCE DATA; NERVE GROWTH FACTORS; RECEPTORS, TRANSFERRIN; RECOMBINANT FUSION PROTEINS;

EID: 0031035331     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4547(19970115)47:2<123::AID-JNR1>3.0.CO;2-H     Document Type: Article

References (69)

1. Aloe L (1987): Intracerebral pretreatment with nerve growth factor prevents irreversible brain lesions in neonatal rats injected with ibotenic acid. Biotechnology 5:1085-1086.
2. Bacha P, Murphy JR, Reichlin S (1983): Thyrotropin-releasing hormone-diphtheria toxin-related polypeptide conjugates. Potential role of the hydrophobic domain in toxin entry. J Biol Chem 258:1565-1570.
3. Barde YA (1989): Trophic factors and neuronal survival. Neuron 2:1525-1534.
4. Bartus RT, Dean RLI, Beer B, Lippa AS (1982): The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408-417.
5. Bartus RT, Flicker C, Dean RL, Pontecorvo M, Figueiredo J, Ficher SK (1985): Selective memory loss following nucleus basalis lesions: Long term behavioral recovery despite persistent cholinergic deficiencies. Pharmacol Biochem Behav 23:125-135.
6. Bebbington CR (1991): Expression of antibody genes in nonlymphoid mammalian cells. Methods: A Companion to Methods in Enzymology 2:136-145.
7. Blattler WA, Lambert JM, Goldmacher VS (1989): Realizing the full potential of immunotoxins. Cancer Cells 1:50-55.
8. Bradshaw RA, Murray-Rust J, Ibanez CF, McDonald NQ, Lapatto R, Blundell TL (1994): Nerve growth factor: Structure/function relationships. Protein Sci 3:1901-1913.
9. Brightman MW (1977): Morphology of blood-brain interfaces. Exp Eye Res 25 (Suppl):1-25.
10. Broadwell RA, Banks WA (1993): A cell biological perspective for the transcytosis of peptides and proteins through the mammalian blood-brain fluid barriers. In Pardridge WA (ed): "The Blood-Brain Barrier: Cellular and Molecular Biology." New York: Raven Press, pp 165-199.
11. Buchner J, Pastan I, Brinkmann U (1992): A method for increasing the yeild of properly folded recombinant fusion proteins: Single chain immunotoxins from renaturation of bacterial inclusion bodies. Anal Biochem 205:263-270.
12. Casadei J, Powell MJ, Kenten JH (1990): Expression and excretion of aequorin as a chimeric antibody by means of a mammalian expression vector. Proc Natl Acad Sci USA 87:2047-2051.
13. Chomczynski P, Sacchi N (1987): Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159.
14. Coloma MJ, Hastings A, Wims LA, Morrison SL (1992): Novel vectors for the expression of antibody molecules using variable regions generated by polymerase chain reaction. J Immunol Methods 152:89-104.
15. Davies SW, Beardsall K (1992): Nerve growth factor selectively prevents excitotoxin induced degeneration of striatal cholinergic neurons. Neurosci Lett 140:161-164.
16. Dinkwater CC, Barker PA, Suter U, Shooter EM (1993): The carboxyl terminus of nerve growth factor is required for biological activity. J Biol Chem 268:23202-23207.
17. Ebendal T (1989a): NGF in CNS: Experimental data and clinical implications. Prog Growth Factor Res 1:143-159.
18. Ebendal T (1989b): Use of collagen gels to bioassay nerve growth factor activity. In Rush RA (ed): "IBRO Handbook Series: Methods in the Neurosciences." Chichester: John Wiley & Sons, pp 81-93.
19. Edwards S, Selby MJ, Garcia PD, Rutter WJ (1988): Processing of the native growth factor precursor to form biologically active nerve growth factor. J Biol Chem 263:6810-6815.
20. Fischer W, Wictorin K, Bjorklund A, Williams LR, Varon S, Gage FH (1987): Intracerebral infusion of nerve growth factor ameliorates cholinergic neuron atrophy and spatial memory impairments in aged rats. Nature 329:65-68.
21. Fischer W, Gage FH, Bjorklund A (1989): Degenerative nerve changes in forebrain cholinergic nuclei correlated with cognitive impairments in aged rats. Eur J Neurosci 1:34-45.
22. Friden PM, Walus LR, Musso GF, Taylor MA, Malfroy B, Starzyk RM (1991): Anti-transferrin receptor antibody and antibody-drug conjugate cross the blood-brain barrier. Proc Natl Acad Sci USA 88:4771-4775.
23. Friden PM, Walus LR, Watson P, Doctrow SR, Kozarich JW, Backman C, Bergman H, Hoffer B, Bloom F, Granholm AC (1993): Blood-brain barrier penetration and in vivo activity of an NGF conjugate. Science 259:373-377.
24. Friden PM, Olson TS, Obar R, Walus LR, Putney SD (1996) Chacterization, receptor mapping and blood-brain barrier transcytosis of antibodies to the human transferrin receptor. J Pharm Exp Ther 278:1491-1498.
25. Gavilondo-Cowley JV, Coloma MJ, Vazquez J, Ayala M, Macias A, Fry KE, Larrick JW (1990): Specific amplification of rear-ranged immunoglobin variable region genes from mouse hybridoma cells. Hybridoma 9:407-417.
26. Hefti F (1986): Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transections. J Neurosci 6:2155-2162.
27. Hefti F, Hartikka J, Knusel B (1989): Function of neurotrophic factors in the adult and aging brain and their possible use in the treatment of neurodegenerative diseases. Neurobiol Aging 10:515-533.
28. Hempstead BL, Rabin SJ, Kaplan L, Reid S, Parada L, Kaplan DR (1992): Overexpression of the trk tyrosine kinase rapidly accelerates nerve growth factor-induced differentiation. Neuron 9:883-896.
29. Hoogenboom HR, Volckaert G, Raust JCM (1991): Construction and expression of antibody-tumor necrosis factor fusion proteins. Mol Immunol 28:1027-1037.
30. Hunt AJ, Lynch PD, Londo T, Dimond P, Gordon NF, McCormack T, Schutz A, Percoski M, Cao X, McGrath JP, Putney S, Hamilton RA (1995): Development and monitoring of purification process for nerve growth factor fusion antibody. J Chromatogr A 708:61-70.
31. Huston JS, Mudgett-Hunter M, Tai MS, McCartney J, Warren F, Haber E, Oppermann H (1991). Protein engineering of single-chain Fv analogs and fusion proteins. In Langone JJ (ed): "Methods in Enzymology." San Diego: Academic Press, pp 46-88.
32. Jaenicke R (1987): Folding and association of proteins. Prog Biophys Mol Biol 49:117-237.
33. Jeffries WA, Brandon MR, Hunt SV, Williams AF, Gatter KC, Mason DY (1984): Transferrin receptor on endothelium of brain capillaries. Nature 312:162-163.
34. Johnson GVW, Simonato M, Jope RS (1988): Dose- and time-dependent hippocamal cholinergic lesions induced by ethylcholone mustard aziridinium ion: Effects of nerve growth factor, GM1 ganglioside, and vitamin E. Neurochem Res 13:685-692.
35. Kabat EA, Wu TT, Perry HM, Gottesman KS, Foeller C (1991): Sequences of Proteins of Immunological Interest, 5th edition. Public Health Service, National Institutes of Health, Bethesda, Maryland, pp. 7-16, 29-39.
36. Kordower JH, Mufson EJ, Granholm A, Hoffer B, Friden F (1993): Delivery of trophic factors to the primate brain. Exp Neurol 124:21-30.
37. Kordower JH, Charles V, Bayer R, Bartus RT, Putney SD, Walus LR, Friden PM (1994): Intravenous administration of an antibody-nerve growth factor conjugate prevents degeneration of cholinergic striatal neurons in a model of Huntington disease. Proc Natl Acad Sci USA 91:9077-9080.
38. Kozak M (1986): Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. Cell 44:283-292.
39. Kromer LF (1987): Nerve growth factor treatment after brain injury prevents neuronal death. Science 235:214-216.
40. Larrick JW, Danielsson L, Brenner CA, Wallace EF, Abrahamson M, Fry KE, Borrebaeck CAK (1989): Polymerase chain reaction using mixed primers: Cloning of human monoclonal antibody variable region genes from single hybridoma cells. Bio/Technology 7:934-938.
41. Levi-Montalcini R (1987): The nerve growth factor 35 years later. Science 237:1154-1162.
42. Luo Y, Neet KE (1992): The unprocessed C-terminal dipeptide of recombinant beta-nerve growth factor determines three stable forms with distinct biological activities. J Biol Chem 187: 12275-12283.
43. McDonald NQ, Chao MV (1995): Structural determinants of neurotrophin action. J Biol Chem 270:19669-19672.
44. McDonald NQ, Lapatto R, Murray-Rust J, Gunning J, Wlodawer A, Blundell TL (1991): New protein fold revealed by a 2.3 A resolution crystal structure of nerve growth factor. Nature 354: 411-414.
45. Mobley WC (1989): Nerve growth factor in Alzheimer's disease: To treat or not to treat? Neurobiol Aging 10:578-580.
46. Murray CL, Fibiger HC (1985): Learning and memory deficits after lesions of the nucleus basalis magnocellularis: Reversal by physostigmine. Neuroscience 14:1025-1032.
47. Nanduri J, Vroegop SM, Buxser SE, Neet KE (1994): Immunological determinants of nerve growth factor involved in p 140 (trk) receptor binding. J Neurosci Res 37:433-444.
48. 11C-nicotine binding, blood flow, EEG and verbal episodic memory in an Alzheimer's patient (case report). J Neural Transm 4:79-95.
49. Pardridge WM (1986): Receptor-medated peptide transport through the blood-brain barrier. Endocrine Rev 7:299-304.
50. Pardridge WM, Bucial JL, Friden PM (1991): Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo. J Pharm Exp Ther 259:66-70.
51. Pastan I, Fitzgerald D (1991): Recombinant toxins for cancer treatment. Science 254:1173-1177.
52. Pastan I, Chaudhary V, FitzGerald DJ (1992): Recombinant toxins as novel therapeutic agents. In Richardson CC, Abelson JN, Walsh CT (eds): Palo Alto, CA: Annual Reviews, Inc., pp 331-354.
53. Pastan J, Fitzgerald D (1989): Pseudomonas exotoxin: Chimeric toxins. J Biol Chem 264:15157-15160.
54. Raag R, Whitlow M (1995): Single-chain Fvs. FASEB J 9:73-80.
55. Reese TS, Karnovsky MJ (1967): Fine structural localization of a blood-brain barrier to exogenous peroxidase. J Cell Biol 34: 207-217.
56. Runge MS, Quertermous T, Zavodny PJ, Love TW, Bode C, Frietag M, Shaw S-Y, Huang PL, Chou C-C, Mullins D, Schnee JM, Savard CE, Rothenberg ME, Newell JB, Matsueda GR, Haber E (1991): A recombinant chimeric plasminogen activator with high affinity for fibrin has increased thrombolytic potency in vitro and in vivo. Proc Natl Acad Sci USA 88:10337-10341.
57. Saffran BN, Woo JE, Mobley WC, Crutcher KA (1989): Intraventricular NGF infusion in the mature rat brain enhances sympathetic innervation of cerebrovascular targets but fails to elicit sympathetic ingrowth. Brain Res 492:245-254.
58. Schmelzer CH, Burton LB, Chan W-P, Martin E, Gorman C, Canova-Davis E, Ling VT, Sliwkowski MB, McCray G, Briggs JA, Nguyen TH, Polastri G (1992): Biochemical characterization of recombinant human nerve growth factor. J Neurochem 59: 1675-1683.
59. Schumacher JM, Short MP, Hyman BT, Breakfield XO, Isacson O (1991): Intracerebral implantation of nerve growth factor-producing fibroblasts protects striatum against neurotoxic levels of excitatory amino acids. Neuroscience 43:567-570.
60. Shin S, Friden P, Moran M, Morrison SL (1994): Functional properties of antibody insulin-like growth factor fusion proteins. J Biol Chem 269:4979-4985.
61. Soderstrom S, Hallbook CF, Ibanez CF, Persson H, Ebendal T (1990): Recombinant human beta-nerve growth actor (NGF): Biological activity and properties in an enzyme immunoassay. J Neurosci Res 27:665-677.
62. Suter U, Heymach JV, Shooter EM (1991): Two conserved domains in the NGF propeptide are necessary and sufficient for the biosynthesis of correctly processed and biologically active NGF. EMBO J 10:2395-2400.
63. Thoenen H, Bandtlow C, Heumann R (1987): The physiological function of nerve growth factor in the central nervous system: comparison with the periphery. Rev Physiol Biochem Pharmacol 109:145-178.
64. Tijssen P, Kurstak E (1984): Highly efficient and simple methods for the preparation of peroxidase and active peroxidase-antibody conjugates for enzyme immunoassays. Anal Biochem 136: 451-457.
65. Ulrich A, Gray A, Berman C, Dull TJ (1983): Human nerve growth factor gene sequence highly homologous to that of mouse. Nature 303:821-825.
66. Vitetta ES, Fulton RJ, May RD, Till M, Uhr JW (1986): Redesigning nature's poisons to create anti-tumor reagents. Science 238: 1098-1104.
67. White SRT, Seligman PA, Rutherford M, Trowbridge IS (1990): Combinations of anti-transferrin receptor monoclonal antibodies inhibit human tumor cell growth in vitro and in vivo: Evidence for synergistic antiproliferative effects. Cancer Res 50: 6295-6301.
68. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, DeLong MR (1982): Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain. Science 215:1237-1239.
69. Williams LR, Varon S, Peterson GM, Wictorin K, Fisher W, Bjorklund A, Gage FH (1986): Continuous infusion of nerve growth factor prevents forebrain neuronal death after fimbria-fornix transection. Proc Natl Acad Sci USA 83:9231-9235.